Clarity Pharmaceuticals Ltd. ((AU:CU6)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clarity Pharmaceuticals Ltd. is conducting a Phase 3 clinical study titled ’64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer.’ The study aims to assess the effectiveness of 64Cu-SAR-bisPSMA PET/CT in detecting recurrent prostate cancer, which is crucial for improving diagnostic accuracy and patient outcomes.
The intervention being tested is a drug called 64Cu-SAR-bisPSMA, administered as a single bolus injection. This experimental treatment is designed to enhance imaging capabilities for detecting prostate cancer recurrence.
The study follows an interventional design with a single-group model, focusing on diagnostic purposes. There is no allocation or masking involved, simplifying the study’s execution and analysis.
The study began on April 29, 2025, with the latest update submitted on July 14, 2025. These dates are significant as they mark the study’s progress and ongoing recruitment status.
This study update could positively impact Clarity Pharmaceuticals’ stock performance by highlighting their innovative approach in prostate cancer diagnostics. The progress may attract investor interest, especially in comparison to competitors in the oncology diagnostics sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.